Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma

Pneumonitis is a serious adverse event of EGFR-TKI treatment. Although several cases of EGFR-TKI rechallenge after EGFR-TKI-induced pneumonitis have been reported, little is known about post-pneumonitis osimertinib rechallenge. We describe a 69-year-old never-smoking Japanese woman with postoperativ...

詳細記述

保存先:
書誌詳細
出版年:Respir Med Case Rep
主要な著者: Satoh, Shingo, Shiroyama, Takayuki, Tamiya, Motohiro, Nasu, Shingo, Tanaka, Ayako, Morita, Satomu, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Hirashima, Tomonori
フォーマット: Artigo
言語:Inglês
出版事項: Elsevier 2017
主題:
Case Report
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805846/
https://ncbi.nlm.nih.gov/pubmed/29487786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.12.005
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料